论文部分内容阅读
目的探讨进展期胃癌手术后辅助替吉奥(S-1)同步放射治疗的疗效及安全性。方法入组68例进展期胃癌手术后患者,随机分为观察组(术后同步放化疗组)和对照组(术后单纯化疗组),每组各34例。术后3～4周开始,观察组患者行3D-CRT放射治疗同步S-1化疗,对照组患者采用单药S-1化疗,观察两组患者生存时间及不良反应。结果观察组患者1、2和3年总生存率分别为78.0%、58.2%和52.0%,中位生存时间为29个月。对照组患者1、2和3年总生存率分别为67.8%、33.0%和22.0%,中位生存时间为18个月。两组患者生存率差异有统计学意义(P=0.029)。观察组不良反应主要为胃肠道反应,两组均顺利完成治疗计划。结论进展期胃癌手术后辅助S-1同步放射治疗可提高生存率,不良反应可以耐受。
Objective To investigate the efficacy and safety of adjuvant T-1 synchrotron radiation after advanced gastric cancer surgery. Methods Sixty-eight patients with advanced gastric cancer who underwent surgery were randomly divided into observation group (postoperative concurrent chemoradiotherapy group) and control group (postoperative chemotherapy alone group), 34 cases in each group. The patients in the observation group were treated with 3D-CRT radiotherapy simultaneously with S-1 chemotherapy after 3 to 4 weeks. The patients in the control group were treated with S-1 chemotherapy alone. The survival time and adverse reactions of the two groups were observed. Results The 1, 2 and 3-year overall survival rates in the observation group were 78.0%, 58.2% and 52.0%, respectively. The median survival time was 29 months. The 1, 2 and 3-year overall survival rates in the control group were 67.8%, 33.0% and 22.0%, respectively, with a median survival of 18 months. There was a significant difference in survival between the two groups (P = 0.029). Adverse reactions in the observation group were mainly gastrointestinal reactions, and both groups successfully completed the treatment plan. Conclusions Assisted S-1 synchronous radiotherapy after advanced gastric cancer surgery can improve the survival rate and adverse reactions can be tolerated.